Superluminal partners with Eli Lilly to advance AI-driven small molecule therapeutics for cardiometabolic diseases.

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology announced a collaboration with Eli ...

Collaboration combines LTZ’s first-in-class Myeloid Engager Platform with Lilly’s world-class expertise in research, development and commercialization LTZ Therapeutics (“LTZ”), an ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.

"Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight management.

Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index.

Investors were spooked by a peer's notable reduction in sales and profitability guidance. This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity ...

Eli Lilly (LLY 2.95%) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index.

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity ...